Page 4 - Phasei Program News Today

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of trastuzumab deruxtecan in difficult-to-treat HER2-positive solid tumors.

Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.

Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

Results of the Canadian Cancer Trials Group CX.5/SHAPE trial could lead to surgical de-escalation among patients with cervical cancer.